Evidence map›Paper›PMID 42439787›Full record

ReviewJournal of primary care & community health

Smoking Cessation in Primary Care: A Narrative Review of Evidence-Based Treatment, Emerging Technology, and Harm Reduction Approaches.

Ivana T Croghan, Ryan T Hurt, Muhamad Y Elrashidi, Timothy J Milbrandt, Aditya K Ghosh, Shawn C Fokken, Jon O Ebbert

Registry-linked trialAbstract readReview
In one paragraph

Review in Journal of primary care & community health. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07487818 (Using Vagal Nerve Stimulation In Conjunction With NRT For Smoking Cessation), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07487818 phase2 / phase3recruitingnot on this map

Using Vagal Nerve Stimulation In Conjunction With NRT For Smoking Cessation

TypeinterventionalSponsorMayo ClinicRan2026 to 2027Enrolled150ConditionsSmoking CessationArmsNon-invasive vagus nerve stimulator plus nicotine replacement patches, nicotine replacement patches
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ivana T CroghanDepartment of Medicine, Division of General Internal Medicine, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0003-3464-3525
Ryan T HurtDepartment of Medicine, Division of General Internal Medicine, Mayo Clinic, Rochester, MN, USA.
Muhamad Y ElrashidiDepartment of Medicine, Division of Community Internal Medicine, Geriatrics and Palliative Care, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0002-9139-4783
Timothy J MilbrandtDepartment of Medicine, Nicotine Dependence Center, Mayo Clinic, Rochester, MN, USA.
Aditya K GhoshDepartment of Medicine, Division of General Internal Medicine, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0002-9247-5999
Shawn C FokkenDepartment of Medicine, Division of General Internal Medicine, Mayo Clinic, Rochester, MN, USA.
Jon O EbbertDepartment of Medicine, Division of Community Internal Medicine, Geriatrics and Palliative Care, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0002-7975-3704

Funding

Using Vagal Nerve Stimulation in Conjunction with NRT for Smoking CessationR21CA302802 · NCI · MAYO CLINIC ROCHESTER · PI CROGHAN, IVANA TALLERICO, HURT, RYAN THOMAS · 2025 to 2025
$412k
NCI NIH HHS R21 CA302802
6 · The paper itself

Abstract

Conventional cigarette smoking remains a leading preventable cause of morbidity and mortality despite declining prevalence, yet evidence-based treatments remain underused. This narrative review examines guideline-supported therapies and emerging approaches, including digital tools, neuromodulation, and harm-reduction strategies. Standard care typically combines FDA-approved pharmacotherapy with behavioral counseling. Digital interventions can extend access and support adherence, particularly when integrated with pharmacotherapy and follow-up. Repetitive transcranial magnetic stimulation (rTMS) can be considered as an adjunctive option for patients who do not respond to pharmacotherapy and is FDA-approved. For patients unable to quit, structured harm-reduction strategies may help reduce risk while supporting progression toward eventual abstinence. These approaches should be used alongside, not in place of, guideline-recommended pharmacotherapy and behavioral counseling, which remain the gold standard for care. This review outlines a pragmatic, primary care-oriented model that integrates stepped-care with harm-reduction strategies.

Indexed as

Harm ReductionPrimary Health CareSmoking CessationBehavior TherapyHumansTobacco Use Cessation DevicesTobacco Use DisorderTranscranial Magnetic Stimulationbehavioral therapyharm reductionnicotine dependenceprimary health caresmoking cessationtelemedicinetobacco cessation devicestobacco use disorder

Identifiers

PMID42439787
PMCPMC13365700

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.